Amanda Lanier

Production Editor at BioWorld

Featured in: Favicon

bioworld.com Favicon

flatheadbeacon.com Favicon

dailyinterlake.com Favicon

wiley.com

tmc.edu

onlinelibrary.wiley.com

Articles

Med-tech M&A hits $10.93B in Q1 despite March value plunge

1 week ago | bioworld.com | Amanda Lanier

Med-tech M&A hits $10.93B in Q1 despite March value plungeDespite a sharp drop in March, total med-tech M&A deal value for the first quarter of 2025 remained significantly higher than last year’s, reaching $10.93 billion compared to $3.63 billion in Q1 2024, though still down from $22.56 billion in Q1 2023. BioWorld MedTech Analysis and data insight Financings
Biopharma sees Q1 financings pullback, but private funding climbs

1 week ago | bioworld.com | Amanda Lanier

Biopharma financings 1Q25Biopharma sees Q1 financings pullback, but private funding climbs Biopharma companies brought in $13.08 billion in financing during the first quarter (Q1) of 2025, marking a significant drop from every quarter of 2024. The number of financings also declined, with 239 transactions completed in Q1 this year, down from a quarterly average of approximately 299 deals in 2024. BioWorld Analysis and data insight Financings IPO
Ten March deals passed $1B, totaling $25.31B in value

1 week ago | bioworld.com | Amanda Lanier

Biopharma deals March 2025Ten March deals passed $1B, totaling $25.31B in valueBiopharma dealmaking surged in the first quarter of 2025, totaling $66.86 billion, well ahead of the $44.16 billion recorded in the same period last year. March contributed $29.48 billion to the total, a 237% increase from February’s $8.76 billion and closely matching January’s $28.63 billion. BioWorld Analysis and data insight Deals and M&A
Trial misses sink cancer stocks in Q1: Mersana, Cargo, Mural fall

2 weeks ago | bioworld.com | Amanda Lanier

Trial misses sink cancer stocks in Q1: Mersana, Cargo, Mural fall The BioWorld Cancer Index ended the first quarter (Q1) of 2025 down 4.74%, retreating after a promising start that saw the index rise 5.78% by the end of January. In the first quarter, 20 stocks declined in value while just nine posted gains. BioWorld Analysis and data insight Cancer
Private biopharma financings jump to $2B in March, up from $1B

2 weeks ago | bioworld.com | Amanda Lanier

Biopharma financings March 2025Private biopharma financings jump to $2B in March, up from $1BBiopharma companies secured $3.82 billion across 81 public and private financings in March 2025, marking a 28% increase from the $2.98 billion raised through 59 transactions in February. BioWorld Asia Analysis and data insight Financings IPO
2seventy, TG, Springworks lead cancer index among Q1 market falls

2 weeks ago | bioworld.com | Amanda Lanier

2seventy, TG, Springworks lead cancer index among Q1 market fallsAfter gaining 5.78% in January, the BioWorld Cancer Index reversed course, falling 4.74% year-to-date by the end of March. The index’s movement has closely tracked broader market trends. The Nasdaq Biotechnology Index climbed to 5.15% at the end of January but ended the first quarter down 1.54%. Similarly, the Dow Jones Industrial Average rose 4.7% in the first month of the year before slipping to a 1.28% loss through March.
Private biopharma financings jump to $2B in March, up from $1B

2 weeks ago | bioworld.com | Amanda Lanier

Biopharma financings March 2025Private biopharma financings jump to $2B in March, up from $1BBiopharma companies secured $3.82 billion across 81 public and private financings in March 2025, marking a 28% increase from the $2.98 billion raised through 59 transactions in February. Despite the monthly gain, total funding for the first quarter (Q1) reached $13.08 billion, down 72% compared to the $47.25 billion in Q1 2024. BioWorld Analysis and data insight Financings IPO
Med-tech Q1 financing rose 28% year over year to $8.27B

2 weeks ago | bioworld.com | Amanda Lanier

Med-tech Q1 financing rose 28% year over year to $8.27BMed-tech companies brought in $1.96 billion across 41 financings in March 2025, marking a decline from the $3.52 billion raised in 65 transactions the month prior. Despite the monthly dip, the sector remains on solid footing. BioWorld MedTech Financings
February’s phase III wins include Qyuns’ ankylosing spondylitis data

3 weeks ago | bioworld.com | Amanda Lanier

Biopharma clinical updates February 2025February’s phase III wins include Qyuns’ ankylosing spondylitis dataIn February 2025, BioWorld recorded 148 updates from phase I to phase III trials, marking a decline from the 171 updates tracked in January. BioWorld Asia Analysis and data insight Clinical
February’s phase III wins include Qyuns’ ankylosing spondylitis data

3 weeks ago | bioworld.com | Amanda Lanier

Biopharma clinical updates February 2025February’s phase III wins include Qyuns’ ankylosing spondylitis dataIn February 2025, BioWorld recorded 148 updates from phase I to phase III trials, marking a decline from the 171 updates tracked in January. The month saw 13 positive phase III trial results, while three studies ended in failure. BioWorld Analysis and data insight Clinical